Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Jodie P. Morrison has assumed the chair role of its board of directors, effective July 15, 2020. Ms. Morrison brings more than 20 years of executive leadership and therapeutics development expertise within the biopharmaceutical industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005242/en/

Jodie P. Morrison Chair, Board of Directors, Ribon Therapeutics (Photo: Business Wire)

“We are honored to welcome Jodie as chair of our board of directors, particularly given her proven track record as an accomplished biotech executive who understands how to build companies and has a wealth of operational, clinical and business development expertise,” said Victoria Richon, President and CEO, Ribon Therapeutics. “Her expertise is an invaluable addition to our board as we continue to advance the company and our first-in-class oncology programs.”

“I am impressed with Ribon’s unique platform and demonstrated ability to successfully translate their pioneering research on stress response pathways to the clinic, where their ongoing work has the potential to address significant unmet needs in oncology,” said Jodie P. Morrison. “It is an honor to join the board and I look forward to working to create significant value for both patients and shareholders.”

Ms. Morrison is an accomplished biopharmaceutical executive who brings more than 20 years of operational, business and development experience in oncology, neurology and orphan drug programs, having successfully guided the growth and development of emerging biopharmaceutical companies across multiple therapeutic areas. Ms. Morison is currently the Chief Executive Officer of Cadent Therapeutics. Previous roles include serving as interim CEO at Keryx Biopharmaceuticals, Inc. (at the time of the merger with Akebia), acting Chief Operating Officer at Syntimmune (acquired by Alexion), and President and CEO of Tokai Pharmaceuticals. Prior to being appointed President and Chief Executive Officer at Tokai, Ms. Morrison held other senior positions with the company, including Chief Operating Officer, Head of Clinical Affairs and Program Operations, and Vice President of Clinical Affairs and Program Operations. Prior to joining Tokai, Ms. Morrison held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc.

Ms. Morrison received a B.A. in neuroscience from Mount Holyoke College, her clinical research certification from Boston University School of Medicine, and her business training through the Greater Boston Executive Program at the MIT Sloan School of Management. Ms. Morrison currently sits on the board of directors for Cadent Therapeutics and Aileron Therapeutics.

About Ribon Therapeutics
Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD⁺ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts. For more information visit www.RibonTx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005242/en/